Feed VRTX
VR

Vertex Pharmaceuticals VRTX · NASDAQ

$514.65 +2.53% (+$12.70)

Market cap
$127.2B
Enterprise value
$123.1B
P/E
28.9x
Forward P/E
28.1x
PEG
-
P/S
10.1x
P/FCF
33.5x
EV/EBITDA
22.6x
ROIC
17.3%
Gross margin
86.0%
Net margin
34.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-0.8x
Beta
0.32
Free float
99.8%

About the company

Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.

Sector

Healthcare

Industry

Biotechnology

CEO

Reshma Kewalramani

Employees

6,400

Headquarters

Boston

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.